Atara Biotherapeutics Inc

Atara Biotherapeutics Inc has a negative net equity of -$98.31 million, indicating a significant equity deficit, and a current ratio of 0.59, suggesting limited short-term liquidity. The company's cash and equivalents of $35.09 million are partially offset by long-term debt of $36.52 million, resulting in a negative net cash position. The liquidity risk is compounded by a free cash flow of -$30.49 million, reflecting ongoing cash outflows from operations. The company's profitability is challenged, with a net loss of $31.75 million and an operating loss of $31.25 million. The return on equity of 0.323 is positive but misleading due to the negative equity base, while the return on assets of -0.1921 indicates poor asset utilization. Gross profit of $25.37 million is insufficient to cover operating expenses, highlighting the need for cost optimization or revenue growth. Geographic and segment exposure is not disclosed in the available data, but the company's revenue of $27.36 million is likely concentrated in a limited number of therapeutic areas. The absence of detailed segment reporting limits visibility into the drivers of performance or risk. The company's growth trajectory is uncertain, with no specific revenue growth rates provided. The operating cash flow of -$29.61 million and free cash flow of -$30.49 million suggest ongoing operational challenges. The capital expenditure of -$127,000 indicates minimal investment in long-term assets, which may limit future growth potential. The risk assessment highlights medium liquidity risk and low dilution risk. The negative net equity and high debt-to-equity ratio of -0.37 underscore the company's financial fragility. The absence of strong buy analyst recommendations and the mean price target of $9.33, below the current market price of $9.59, suggest limited upside potential. Recent events include analyst estimates with a mean price target of $9.33 and a median of $6.00, indicating a wide range of expectations. The lack of strong buy ratings and the presence of two buy and one hold recommendation suggest cautious investor sentiment. No recent filings or transcripts are provided to assess management commentary or strategic direction.